AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 163 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.72 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $1,000 | – | 45 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | – | 0 | – | 0.00% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q4 2018 | $18,000 | -41.9% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $31,000 | -24.4% | 500 | -16.7% | 0.00% | -50.0% |
| Q2 2018 | $41,000 | +13.9% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $36,000 | 0.0% | 600 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $36,000 | +50.0% | 600 | +20.0% | 0.00% | +100.0% |
| Q3 2017 | $24,000 | +14.3% | 500 | +25.0% | 0.00% | 0.0% |
| Q2 2017 | $21,000 | +16.7% | 400 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $18,000 | +20.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $15,000 | 0.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $15,000 | +114.3% | 400 | 0.0% | 0.00% | – |
| Q2 2016 | $7,000 | +40.0% | 400 | +100.0% | 0.00% | – |
| Q4 2015 | $5,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |